Novo Nordisk to spend more on acquisitions and external innovation
![Photo: Novo Nordisk / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13363813.ece/ALTERNATES/schema-16_9/doc7hxteb92nrk17k2lecm7.jpg)
Novo Nordisk's successful GLP-1 drug is creating new opportunities for the Danish pharmaceutical giant, which has stated it can no longer rely exclusively on drugs developed in-house, Danish financial daily Børsen reports.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk hires Queen Latifah for US marketing offensive
For subscribers